- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.50 Å
- Oligo State
- monomer
- Ligands
- 1 x TKO: (4M)-6-bromo-4-(furan-2-yl)quinazolin-2-amine(Non-covalent)
- 3 x CLR: CHOLESTEROL(Non-covalent)
CLR.2: 8 residues within 4Å:- Chain A: L.368, P.369, I.372, C.383, S.384, L.390
- Ligands: OLA.21, OLA.22
6 PLIP interactions:6 interactions with chain A- Hydrophobic interactions: A:L.368, A:P.369, A:I.372, A:L.390
- Hydrogen bonds: A:S.384, A:S.384
CLR.3: 8 residues within 4Å:- Chain A: L.212, C.375, F.376, F.379, C.380
- Ligands: OLC.7, OLA.22, OLA.25
6 PLIP interactions:6 interactions with chain A- Hydrophobic interactions: A:L.212, A:F.376, A:F.376, A:F.376, A:F.379, A:F.379
CLR.4: 9 residues within 4Å:- Chain A: F.87, F.95, A.97, A.98, G.101, I.105, Q.188
- Ligands: OLC.5, OLA.24
6 PLIP interactions:6 interactions with chain A- Hydrophobic interactions: A:F.87, A:F.95, A:A.97, A:I.105
- Hydrogen bonds: A:A.98, A:Q.188
- 4 x OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate(Non-covalent)
OLC.5: 10 residues within 4Å:- Chain A: V.82, L.83, P.86, F.87, T.90, F.95, C.96, Q.188
- Ligands: CLR.4, OLA.10
8 PLIP interactions:8 interactions with chain A- Hydrophobic interactions: A:V.82, A:L.83, A:P.86, A:F.87, A:T.90, A:F.95
- Hydrogen bonds: A:C.96, A:Q.188
OLC.6: 9 residues within 4Å:- Chain A: C.53, V.56, W.57, Y.68, V.71, A.75
- Ligands: OLC.8, OLA.18, OLA.24
2 PLIP interactions:2 interactions with chain A- Hydrophobic interactions: A:W.57, A:V.71
OLC.7: 7 residues within 4Å:- Chain A: F.208, L.212, F.379, P.381, D.382
- Ligands: CLR.3, OLA.19
6 PLIP interactions:6 interactions with chain A- Hydrophobic interactions: A:F.208, A:L.212, A:F.379, A:F.379, A:F.379
- Water bridges: A:D.382
OLC.8: 9 residues within 4Å:- Chain A: Y.68, S.72, G.143, I.150, W.154, F.158
- Ligands: OLC.6, OLA.13, OLA.24
6 PLIP interactions:6 interactions with chain A- Hydrophobic interactions: A:I.150, A:W.154, A:W.154, A:W.154, A:F.158
- Hydrogen bonds: A:G.143
- 17 x OLA: OLEIC ACID(Non-covalent)
OLA.9: 8 residues within 4Å:- Chain A: G.30, V.37, W.389, Y.392, L.393, V.396
- Ligands: OLA.15, OLA.16
Ligand excluded by PLIPOLA.10: 6 residues within 4Å:- Chain A: V.82, T.90, T.93, F.95
- Ligands: OLC.5, OLA.11
Ligand excluded by PLIPOLA.11: 4 residues within 4Å:- Chain A: I.28, I.35, T.93
- Ligands: OLA.10
Ligand excluded by PLIPOLA.12: 6 residues within 4Å:- Chain A: F.69, A.122, I.125, D.126, V.141, I.149
Ligand excluded by PLIPOLA.13: 8 residues within 4Å:- Chain A: A.147, I.150, A.151, W.154, V.155, F.158, A.159
- Ligands: OLC.8
Ligand excluded by PLIPOLA.14: 2 residues within 4Å:- Chain A: I.152, L.156
Ligand excluded by PLIPOLA.15: 4 residues within 4Å:- Chain A: T.400, V.404, F.407
- Ligands: OLA.9
Ligand excluded by PLIPOLA.16: 2 residues within 4Å:- Chain A: W.389
- Ligands: OLA.9
Ligand excluded by PLIPOLA.17: 2 residues within 4Å:- Chain A: W.57
- Ligands: OLA.18
Ligand excluded by PLIPOLA.18: 6 residues within 4Å:- Chain A: C.53, W.54, W.57, I.78
- Ligands: OLC.6, OLA.17
Ligand excluded by PLIPOLA.19: 6 residues within 4Å:- Chain A: Y.204, F.208, V.213, L.216, F.378
- Ligands: OLC.7
Ligand excluded by PLIPOLA.20: 2 residues within 4Å:- Chain A: M.165, L.166
Ligand excluded by PLIPOLA.21: 4 residues within 4Å:- Chain A: P.387, W.389, L.393
- Ligands: CLR.2
Ligand excluded by PLIPOLA.22: 5 residues within 4Å:- Chain A: I.372, F.376, C.383
- Ligands: CLR.2, CLR.3
Ligand excluded by PLIPOLA.23: 4 residues within 4Å:- Chain A: I.28, S.32, T.36, L.39
Ligand excluded by PLIPOLA.24: 6 residues within 4Å:- Chain A: L.83, F.104, F.108
- Ligands: CLR.4, OLC.6, OLC.8
Ligand excluded by PLIPOLA.25: 8 residues within 4Å:- Chain A: L.212, L.215, L.219, Y.222, F.226, A.357, A.360
- Ligands: CLR.3
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Bolteau, R. et al., High ligand efficiency quinazoline compounds as novel A 2A adenosine receptor antagonists. Eur.J.Med.Chem. (2022)
- Release Date
- 2022-08-10
- Peptides
- Adenosine receptor A2a, soluble cytochrome b562 chimera,Soluble cytochrome b562,Adenosine receptor A2a: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A - Membrane
-
We predict this structure to be a membrane protein.
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.50 Å
- Oligo State
- monomer
- Ligands
- 1 x TKO: (4M)-6-bromo-4-(furan-2-yl)quinazolin-2-amine(Non-covalent)
- 3 x CLR: CHOLESTEROL(Non-covalent)
- 4 x OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate(Non-covalent)
- 17 x OLA: OLEIC ACID(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Bolteau, R. et al., High ligand efficiency quinazoline compounds as novel A 2A adenosine receptor antagonists. Eur.J.Med.Chem. (2022)
- Release Date
- 2022-08-10
- Peptides
- Adenosine receptor A2a, soluble cytochrome b562 chimera,Soluble cytochrome b562,Adenosine receptor A2a: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A - Membrane
-
We predict this structure to be a membrane protein.